Paediatric Respiratory Reviews
Volume 8, Issue 2 , Pages 171-176 , June 2007

Bird flu: lessons from SARS

  • Gary W.K. Wong

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Paediatrics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China. Fax: +852 26451570.
    • ,
  • Ting F. Leung

References 

  1. Zhong NS, Wong GW. Epidemiology of severe acute respiratory syndrome (SARS): adults and children. Paediatr Respir Rev. 2004;5:270–274
  2. World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/ (H5N1) Reported to WHO http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_09_19/en/index.html (accessed September 22, 2006).
  3. Wong GW, Hui DS. Severe acute respiratory syndrome (SARS): epidemiology, diagnosis and management. Thorax. 2003;58:558–560
  4. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1986–1994
  5. Wong GW, Fok TF. Severe acute respiratory syndrome (SARS) in children. Pediatr Pulmonol Suppl. 2004;26:69–71
  6. Hon KL, Leung CW, Cheng WT, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet. 2003;361:1701–1703
  7. Wong GW, Li AM, Ng PC, Fok TF. Severe acute respiratory syndrome in children. Pediatr Pulmonol. 2003;36:261–266
  8. Beigel JH, Farrar J, Han AM, Hayden FG, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374–1385
  9. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976
  10. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–1966
  11. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302:276–278
  12. Cheng FW, Ng PC, Chiu WK, et al. A case-control study of SARS versus community acquired pneumonia. Arch Dis Child. 2005;90:747–749
  13. Leung DT, van Maren WW, Chan FK, et al. Extremely low exposure of a community to severe acute respiratory syndrome coronavirus: false seropositivity due to use of bacterially derived antigens. J Virol. 2006;80:8920–8928
  14. Hui DS, Wong GW. Advancements in the battle against severe acute respiratory syndrome. Expert Opin Pharmacother. 2004;5:1687–1693
  15. Leung CW, Chiu WK. Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children. Paediatr Respir Rev. 2004;5:275–288
  16. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet. 2002;360:1831–1837
  17. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136:95–103
  18. Cinatl J, Morgenstern B, Bauer G, et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361:2045–2046
  19. Yu WC, Hui DS, Chan-Yeung M. Antiviral agents and corticosteroids in the treatment of severe acute respiratory syndrome (SARS). Thorax. 2004;59:643–645
  20. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801–2809
  21. Lapinsky SE, Granton JT. Critical care lessons from severe acute respiratory syndrome. Curr Opin Crit Care. 2004;10:53–58
  22. Li AM, So HK, Chu W, et al. Radiological and pulmonary function outcomes of children with SARS. Pediatr Pulmonol. 2004;38:427–433
  23. Yu CC, Li AM, So RC, et al. Longer-term follow up of aerobic capacity in children affected by severe acute respiratory syndrome (SARS). Thorax. 2006;61:240–246
  24. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. Nature. 2005;437:889–893
  25. Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet. 1998;351:467–471
  26. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005;352:333–340
  27. Chan PK. Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis. 2002;34:S58–S64
  28. Claas EC, Osterhaus AD, van Beek R, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 1998;351:472–477
  29. Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis. 1999;180:505–508
  30. Buxton Bridges C, Katz JM, Seto WH, et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis. 2000;181:344–348
  31. Liem NT, Lim W. World Health Organization International Avian Influenza Investigation Team, Vietnam. Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004. Emerg Infect Dis. 2005;11:210–215
  32. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis. 2005;11:201–209
  33. To KF, Chan PK, Chan KF, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol. 2001;63:242–246
  34. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA. 2000;283:1016–1024
  35. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235–1239
  36. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis. 1999;180:254–261
  37. Bresson J-L, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006;367:1657–1664
  38. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006;368:991–997

PII: S1526-0542(07)00033-4

doi: 10.1016/j.prrv.2007.04.003

Paediatric Respiratory Reviews
Volume 8, Issue 2 , Pages 171-176 , June 2007

Article Tools